Shigeo Taniuchi

Profile
Tenure
Apr 2018 – Sep 2022
Years in office
4.4 years
Name in Japanese
谷内樹生
Title at appointment
Representative Director, President and COO
Performance in office
Santen Pharmaceutical
Performance in office
FY2018FY2022Change
Revenue¥224.9billion¥266.3billion+18%
Net margin15.7%10.2%−5.5pt
KurokawaTaniuchiIto
Revenue¥195.3 billionRevenue¥291.6 billionNet margin27.3%Net margin12.8%2013/32016/32021/32026/3
Revenue¥195.3 billionRevenue¥291.6 billionNet margin27.3%Net margin12.8%2013/32016/32021/32026/3
Career

Career

Santen Pharmaceutical

Date Position
Apr 1996 Joined
Oct 2007 Head of China Business, Asia Division, Office, Deputy General Manager
Nov 2008 (中国)有限公司営業本部営業総監 (translation pending)
Apr 2011 General Manager, Business Planning and Administration Office, Asia Division
Apr 2012 General Manager, Corporate Planning Office, Planning Headquarters
Jan 2014 Deputy General Manager of Headquarters, Planning Headquarters
Apr 2015 Executive Officer, Head of Europe Business and President, Santen Holdings EU B.V.
Apr 2016 Managing Executive Officer, Head of Europe Business and President, Santen Holdings EU B.V.
Jun 2017 Director
Apr 2018 Representative Director, President and COO
Oct 2018 General Manager, Asia Division, President and CEO, Santen Inc.
Apr 2019 Head of North America Business, President and CEO, Santen Inc.
Apr 2020 Representative Director, President and CEO
Sep 2022 Stepped down as President